China smartphone shipments slumped in June on inventory overhang: Jefferies
Investing.com - CVRx Inc (NASDAQ:CVRX) received a reiterated Overweight rating and $11.00 price target from Cantor Fitzgerald on Monday. According to InvestingPro data, analyst targets for the stock range from $7.00 to $14.00, suggesting potential upside from current levels. The company maintains a Fair overall financial health score, with notably strong liquidity metrics.
The medical device company reported second-quarter 2025 revenue of $13.6 million, exceeding both Cantor’s estimate of $13.0 million and FactSet consensus of $13.3 million. This represents year-over-year growth of approximately 15%, contributing to the company’s impressive 23.11% revenue growth over the last twelve months. The company maintains a strong gross profit margin of 83.54%.
U.S. Heart Failure revenue reached $12.1 million, also showing year-over-year growth of about 15%. The company expanded its footprint to 240 active implanting centers by quarter-end, adding 13 new centers sequentially.
Cantor Fitzgerald noted encouragement from CVRx’s improvement in implanting centers and mentioned the company’s commentary regarding a more stabilized salesforce.
Recent reimbursement wins and the transition to a CPT 1 Code scheduled for January position CVRx well to drive adoption and revenue growth in 2026, according to the research firm. While the company holds more cash than debt on its balance sheet, InvestingPro analysis reveals several additional key metrics and insights available to subscribers, including detailed financial health scores and growth projections. Get access to the comprehensive Pro Research Report covering this and 1,400+ other US stocks for deeper analysis.
In other recent news, CVRx Inc. reported its earnings for the second quarter of 2025, showing a revenue increase to $13.6 million, surpassing the forecast of $13.29 million. Despite this revenue growth, the company reported a net loss of $0.57 per share, which was larger than the anticipated loss of $0.52 per share. In response to these results, Canaccord Genuity adjusted its price target for CVRx, lowering it from $10.00 to $9.00 while maintaining a Buy rating. This adjustment followed the company’s decision to narrow its full-year revenue guidance, reducing the top end from $58 million to $57 million. These developments reflect the company’s ongoing financial challenges despite revenue achievements. The analysis from Canaccord Genuity suggests a cautious yet optimistic outlook for CVRx. Investors will be closely watching how the company navigates these financial adjustments moving forward.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.